Lundbeck has announced the appointment of Michal Juul Sørensen as Managing Director of its Australian business.
Mr Sørensen succeeds Lorena Di Carlo, who was recently promoted to the role of Vice President and General Manager of Lundbeck’s Neurology Business in the US. He is familiar with Australia, having served as Sales and Marketing Manager for Lundbeck Australia in 2013.
Mr Sørensen has previously served Lundbeck for eight years, during which time he held senior global leadership positions in the company’s portfolios of medicines for depression and schizophrenia. He began his career at Wyeth in the UK and most recently served as Global Brand Director for ALK Abelló in Denmark.
“I am delighted to be returning to Lundbeck in the role of Managing Director in Australia and look forward to leading a dynamic team of people who are dedicated to improving the lives of Australians with mental illness," said Mr Sørensen.
“Lundbeck Australia has recently launched two new products - Abilify Maintena and Brintellix. In addition the company is working towards approval and reimbursement of Rexulti (brexpiprazole), a new treatment for schizophrenia, and in my previous role as Director and Head of Global Marketing (Rexulti) I worked closely on the first global launch of this product in the United States.
“While there are well documented challenges for all innovator pharmaceutical companies operating in Australia, I believe Lundbeck Australia is well positioned for the future with a strong portfolio of existing products and an exciting research pipeline,” Mr Sørensen said.
Herman Santoni, Lundbeck Senior Vice President Asia and MENA, said, “Michal is an excellent fit with the Lundbeck culture. His qualifications, experience in Lundbeck’ s therapeutic areas, dedication and passion for the job will ensure he fulfils the Managing Director’s role with distinction.”
